Oxford scientists expect COVID-19 vaccine data by Christmas


A key researcher at the University of Oxford says scientists expect to report results from the late-stage trials of their COVID-19 vaccine by Christmas

LONDON — University of Oxford scientists expect to report results from the late-stage trials of their COVID-19 vaccine by Christmas, a key researcher said Thursday as he discussed the team’s latest findings.

Dr. Andrew Pollard, an expert in pediatric infection and immunity at Oxford, said research was slowed by low infection rates over the summer, but the Phase III trials are now accumulating the data needed to report results as a renewed surge of the pandemic hits countries around the world. Oxford is developing its vaccine in conjunction with the drugmaker AstraZeneca.

“I think we’re getting close, and it’s definitely going to be before Christmas based on the progress,” Pollard said in an interview with the BBC.

“The reason that we’re so delighted is the we’re seeing the immune responses look exactly the same, even in those who are over 70 years of age,” Pollard said.

The findings were based on a so-called phase II trial of 560 people, including 240 over the age of 70. The results of the peer-reviewed study were published Thursday in the Lancet, an international medical journal.

Phase II vaccine trials provide important preliminary data but don’t prove whether they ultimately prevent people from getting sick. Oxford and AstraZeneca are waiting for the results of phase III trials on thousands of people around the world to show whether their vaccine is safe and effective.

Pollard said there is no competition between the various research teams, because several vaccines will be needed to bring the global pandemic under control and allow life to return to normal.

Pollard, an amateur mountaineer, compared the task to the work involved in climbing a mountain.

“I think we’re still at the bottom of that mountain in some ways,” he said. “We’ve done the route into the bottom of the mountain, the long trek to get to the start. Now we’ve got to get the data about the vaccines in front of regulators for them to scrutinize it and approve the first vaccines. And then we’ve got that huge effort to climb up to the top where we’ve got a vast majority of those who are at risk vaccinated.”



Source link

Get in Touch

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Study sheds light on possible factors leading to obesity-ANI

Tokyo , November 29 (ANI): Research-based on 5,425 citizens' responses to a questionnaire survey has illuminated that obesity causes are linked to various factors...

Airlines preparing to transport COVID-19 vaccine when ready for distribution

American Airlines "successfully moved" thermal packaging in a trial flight.November 29, 2020, 1:48 AM• 4 min readShare to FacebookShare to TwitterEmail this articleThere isn't...

Get in Touch

0FansLike
2,457FollowersFollow
0SubscribersSubscribe

Latest Posts

Study sheds light on possible factors leading to obesity-ANI

Tokyo , November 29 (ANI): Research-based on 5,425 citizens' responses to a questionnaire survey has illuminated that obesity causes are linked to various factors...

Airlines preparing to transport COVID-19 vaccine when ready for distribution

American Airlines "successfully moved" thermal packaging in a trial flight.November 29, 2020, 1:48 AM• 4 min readShare to FacebookShare to TwitterEmail this articleThere isn't...

Washington health officials report more than 2400 new coronavirus cases – KOMO News

Washington health officials report more than 2400 new coronavirus cases  KOMO NewsSource link
Supportscreen tag
%d bloggers like this: